Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, titled West Palm Beach Firefighters' Pension Fund v. Integer Holdings Corporation, et al., No. 1:25-cv-10251 [3]. - Investors have until February 9, 2026, to request to be appointed to lead the case [3]. Group 2: Company Performance and Allegations - Integer designs and manufactures cardiac rhythm management and cardiovascular products, including electrophysiology devices [4]. - The company allegedly overstated demand for its EP devices while public assurances contradicted the reality of falling demand and revenue [5]. - On October 23, 2025, Integer lowered its 2025 sales guidance to between $1.840 billion and $1.854 billion, down from a previous range of $1.850 billion to $1.876 billion, which was below analysts' expectations [6]. - Integer also projected poor net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026, admitting that two of its EP devices had slower than expected adoption [6]. Group 3: Stock Impact - Following the announcement on October 23, 2025, Integer's stock price dropped by $35.22 per share, a decline of over 32%, from $109.11 to $73.89 [6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Integer Holdings Corporation during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Integer common stock between July 25, 2024, and October 22, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by February 9, 2026 [3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019, and has been recognized as a leader in the field of securities class action litigation [4]. Group 3: Case Allegations - The lawsuit alleges that Integer Holdings Corporation made materially false and misleading statements regarding its competitive position in the electrophysiology manufacturing market and the performance of its EP devices [5]. - It is claimed that Integer misrepresented its EP devices as a long-term growth driver for its cardio and vascular segment, leading to investor damages when the true situation was revealed [5].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1]. Company Overview - Integer Holdings Corporation specializes in designing and manufacturing cardiac rhythm management and cardiovascular products, including electrophysiology devices that diagnose and treat arrhythmias [4]. Allegations of Securities Fraud - The lawsuit claims that Integer misrepresented the demand and revenue for its electrophysiology products, which had reportedly fallen sharply, contradicting the company's public statements about sales growth and market position [5][4]. Stock Price Decline - On October 23, 2025, Integer revised its 2025 sales guidance down to between $1.840 billion and $1.854 billion, below analysts' expectations, and projected poor net sales growth of -2% to 2% for 2026. This led to a stock price drop of $35.22 per share, over 32%, from $109.11 to $73.89 [6].

Company Overview - Integer Holdings Corporation is a medical device contract development and manufacturing company, known for its brands Greatbatch Medical and Lake Region Medical [1] - The company specializes in a range of medical applications, particularly in Cardio & Vascular, offering components and devices for various procedures including interventional cardiology and electrophysiology [1] Recent Developments - Irenic Capital Management has acquired a stake of over 3% in Integer Holdings and is advocating for a board refreshment and the exploration of a potential sale of the company [3][6] - Integer's share price has declined nearly 40% over the past year, primarily due to disappointing market demand for specific products, leading to reduced orders from original equipment manufacturers (OEMs) [4][5] Market Position and Challenges - Integer is the largest publicly traded pure-play medical device CDMO, facing limited investor understanding and coverage due to its unique market position [4][6] - The company typically targets organic growth of 6% to 8%, but projections for 2026 have been revised to a range of -2% to 2% [5] Strategic Considerations - Irenic Capital suggests that a sale could be beneficial, as private buyers could conduct thorough due diligence on Integer's products and contracts, which is challenging in a public setting [6][7] - Integer's management previously explored strategic alternatives in 2024, receiving bids at a premium to the share price, indicating potential interest from private equity [7] Board Composition and Governance - Irenic Capital is advocating for a board refreshment to include directors with medical OEM experience and financial expertise, as many current directors have been on the board for over 10 years [8] - The current board's composition may hinder the ability to make transformative decisions regarding the company's future [8][9]

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, titled West Palm Beach Firefighters' Pension Fund v. Integer Holdings Corporation, et al., No. 1:25-cv-10251 [3]. - Investors have until February 9, 2026, to request to be appointed to lead the case [3]. Group 2: Company Performance and Allegations - Integer designs and manufactures cardiac rhythm management and cardiovascular products, including electrophysiology devices [4]. - The company allegedly overstated demand for its electrophysiology devices while public assurances contradicted the actual decline in demand and revenue [5]. Group 3: Stock Price Impact - On October 23, 2025, Integer lowered its 2025 sales guidance to between $1.840 billion and $1.854 billion, down from $1.850 billion to $1.876 billion, which was below analysts' expectations [6]. - The company projected poor net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026, admitting that two of its EP devices had slower than expected adoption [6]. - Following this announcement, Integer's stock price fell by $35.22 per share, a decrease of over 32%, from $109.11 on October 22, 2025, to $73.89 on October 23, 2025 [6].

Core Viewpoint - Investors with significant losses in Integer Holdings Corporation have until February 9, 2026, to file lead plaintiff applications in a securities class action lawsuit due to alleged failure to disclose material information during the Class Period [1][3]. Company Information - Integer Holdings Corporation is facing a class action lawsuit for not disclosing critical information, which is a violation of federal securities laws [3]. - The lawsuit is currently pending in the United States District Court for the Southern District of New York [1]. Financial Performance - On October 23, 2025, Integer disclosed a reduced full-year 2025 sales guidance of $1.840 billion to $1.854 billion, which is significantly below analysts' expectations [4]. - The company also projected net sales growth of -2% to 2% and organic sales growth of 0% to 4% for the full year of 2026, attributed to slower-than-expected market adoption of its products [4]. Stock Price Impact - Following the announcement of the lowered sales guidance, Integer's share price dropped by $35.22, or over 32%, from $109.11 on October 22, 2025, to $73.89 on October 23, 2025 [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Integer Holdings Corporation during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Integer common stock between July 25, 2024, and October 22, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by February 9, 2026 [3] - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4] - The firm has secured significant settlements for investors, including over $438 million in 2019, and has been consistently ranked among the top firms for securities class action settlements [4] Group 3: Case Allegations - The lawsuit alleges that Integer Holdings Corporation made materially false and misleading statements regarding its competitive position in the electrophysiology manufacturing market and the performance of its EP devices [5] - It is claimed that Integer misrepresented its sales and growth prospects, leading to investor damages when the true situation was revealed [5]

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, titled West Palm Beach Firefighters' Pension Fund v. Integer Holdings Corporation, et al., No. 1:25-cv-10251 [3]. - Investors have until February 9, 2026, to request to be appointed to lead the case [3]. Group 2: Company Performance and Allegations - Integer designs and manufactures cardiac rhythm management and cardiovascular products, including electrophysiology devices [4]. - The company allegedly overstated demand for its electrophysiology devices while public assurances contradicted the actual decline in demand and revenue [5]. - On October 23, 2025, Integer lowered its 2025 sales guidance to between $1.840 billion and $1.854 billion, down from a previous range of $1.850 billion to $1.876 billion, which was below analysts' expectations [6]. - Integer also projected poor net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026, admitting that two of its EP devices had slower than expected adoption [6]. Group 3: Stock Impact - Following the announcement of lowered sales guidance, Integer's stock price dropped by $35.22 per share, a decline of over 32%, from $109.11 per share on October 22, 2025, to $73.89 per share on October 23, 2025 [6].

Core Viewpoint - A class action securities lawsuit has been filed against Integer Holdings Corporation, alleging securities fraud that affected investors between July 25, 2024, and October 22, 2025 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that Integer Holdings Corporation materially overstated its competitive position in the electrophysiology manufacturing market [2]. - It is alleged that despite claims of strong visibility into customer demand, the company was experiencing a sustained deterioration in sales related to two of its electrophysiology devices [2]. - The complaint further asserts that Integer mischaracterized its electrophysiology devices as a long-term growth driver for its cardio & vascular segment, leading to materially false and misleading statements about the company's business and prospects [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the relevant time frame have until February 9, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - Rosen Law Firm is reminding purchasers of Integer Holdings Corporation common stock about the upcoming lead plaintiff deadline for a class action lawsuit related to alleged misleading statements made by the company during the specified class period [1][2]. Group 1: Class Action Details - The class period for the lawsuit is from July 25, 2024, to October 22, 2025, inclusive [1]. - Investors who purchased Integer common stock during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by February 9, 2026 [3]. Group 2: Allegations Against Integer Holdings - The lawsuit alleges that Integer made materially false and misleading statements regarding its competitive position in the electrophysiology manufacturing market [5]. - It is claimed that Integer overstated its visibility into customer demand while experiencing a deterioration in sales for two of its electrophysiology devices [5]. - The company mischaracterized its electrophysiology devices as long-term growth drivers for its cardio and vascular segment, leading to misleading positive statements about its business and operations [5].